Status:

COMPLETED

The REALITY Study - Head-to-Head Comparison Between Cypher and Taxus

Lead Sponsor:

Cordis US Corp.

Conditions:

Coronary Artery Disease

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

The main objective of this study is to compare the performance of the Cypher sirolimus-eluting and the Taxus paclitaxel-eluting stent systems in a prospective, multi-center, randomized clinical study.

Detailed Description

This is a prospective, randomized study conducted at 90 centers in Europe, Latin-America and Asia. A total of 1335 patients will be entered into the study and will be randomized on a 1:1 basis to eith...

Eligibility Criteria

Inclusion

  • Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald Classification B\&C, I-II-III) OR patients with documented silent ischemia;
  • Treatment of up to two de novo native coronary artery lesions in a maximum of two major coronary arteries;
  • Ostial lesions;
  • Bifurcations;
  • Target vessel diameter of both lesions must be \>=2.25mm and \<=3.0mm in diameter (visual estimate);
  • One target lesion must be at least 15 mm in length and the second lesion has to be at least 10 mm in length with no upper limit on either;
  • Target lesion stenosis for both lesions is \>50% and \<100% (visual estimate).

Exclusion

  • Patient has experienced a Q-wave or non-Q-wave myocardial infarction with documented total CK \>2 times normal within the preceding 72 hours and the CK and CK-MB enzymes remain above normal at the time of treatment;
  • Has unstable angina classified as Braunwald A I-II-III;
  • Any of the lesions is an unprotected left main coronary disease with \>=50% stenosis;
  • Angiographic evidence of thrombus within target lesion;
  • Heavily calcified lesion and/or calcified lesion, which cannot be successfully predilated (applies to both lesions);
  • Documented left ventricular ejection fraction \<=25%;
  • 8\. Totally occluded vessel (TIMI 0 level) (applies to both lesions);
  • 9\. Prior stent within 10mm of target lesion (applies to both lesions).

Key Trial Info

Start Date :

August 1 2003

Trial Type :

INTERVENTIONAL

End Date :

March 1 2006

Estimated Enrollment :

1335 Patients enrolled

Trial Details

Trial ID

NCT00235092

Start Date

August 1 2003

End Date

March 1 2006

Last Update

April 27 2007

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Institut Hospitalier Jacques Cartier

Massy, France